# Reversible Chemical Modulation of Antibody Effector Function Maintains Anti-tumor Activity While Mitigating Peripheral Immune Activation

Matthew R. Levengood<sup>1</sup>, Chris I. Leiske<sup>1</sup>, Noah A. Bindman<sup>1</sup>, Xinqun Zhang<sup>1</sup>, Nicole Duncan<sup>1</sup>, Weiping Zeng<sup>1</sup>, Serena W. Wo<sup>1</sup>, Abbie Wong<sup>1</sup>, Clark M. Henderson<sup>1</sup>, Karalyne Crowder<sup>1</sup>, Haley D. Neff-LaFord<sup>1</sup>, Django Sussman<sup>1</sup>, Shyra J. Gardai<sup>1</sup>, Philip N. Moquist<sup>1</sup> <sup>1</sup>Seagen Inc., Bothell, WA

## Background


- Removal of fucose on the antibody core glycan increases binding to FcγRIIIa (CD16a) and drives increased antibody-dependent cellular cytotoxicity (ADCC) and immune agonism.
- Robust antibody-Fcγ engagement of non-fucosylated antibodies on immune cells in the periphery can lead to induction of systemic cytokine release and other dose-limiting infusion-related reactions.
- Example: Difference in immune activation for anti-CD40 antibodies is tied to increased FcyRIIIa binding.

Antibody	FcγRIIIa Affinity (K <sub>D</sub> )	RP2D*
Dacetuzumab (hS2C6, SGN-40)	11	8 mg/kg <sup>1</sup>
SEA-CD40 (non-fucosylated hS2C6)	232	10 mcg/kg <sup>2</sup>
	*	Pacammandad Phasa II dasa

- An ongoing challenge in the field of antibody and immuno-oncology therapeutics is identifying a balance between effective engagement of  $Fc\gamma$  receptors that can induce antitumor activity without incurring systemic immune activation.
- A method for the reversible modulation of antibody-Fcγ receptor interactions was designed and applied to several effector-function enhanced antibodies.

# **Technology Overview**

- High concentrations of agonistic antibody levels during infusion can lead to rapid immune activation and cytokine production.
- Goal: Decrease concentration of active species at the time of infusion but restore binding and function over time.
- Strategy:
  - $\circ$  Full conjugation to antibody interchain disulfides impairs FcyR binding at the time of infusion.
  - Reversible linkage of maleimide to mAb cysteines results in deconjugation over time in circulation that then restores binding and function.
  - Use of short, defined polyethylene glycol (PEG) maleimide forms homogeneous conjugates and is inert after deconjugation.



**Scheme 1**. Chemical conjugation to the antibody Fc prevents unwanted peripheral immune engagement and cross-linking at the time of administration. Deconjugation of the blocking groups over time in circulation results in reformation of antibody interchain disulfides and restoration of Fc binding and immune function.

# Results

## **PEGylation of antibody interchain disulfides impairs Fc-FcyR** interactions

Binding of conjugates to FcγRIIIa was assessed using biolayer interferometry (BLI)

Intact antibody Fully conjugated Decreased affinity Highest affinity (8 PEG per Ab) MC-PEG(x) = maleimidocaprov


- Tunable affinity based upon size of PEG Binding to all FcγRs is decreased similarly
- upon PEGylation Binding to FcRn and antigen are not affected
- PEG12 format reduces non-fucosylated binding to wild-type IgG1

SEA-CD40 (non-fucosylated) Conjugate(8)	Fc $\gamma$ RIIIa affinity (K <sub>D</sub> )	
Non-Fucosylated CD40 mAb	11 nM	
Fucosylated CD40 mAb	232 nM	
N-ethyl maleimide	53 nM	
MC-PEG <sub>4</sub>	75 nM	
MC-PEG <sub>8</sub>	169 nM	
MC-PEG <sub>12</sub>	197 nM	
MC-PEG <sub>24</sub>	234 nM	
MC-PEG <sub>36</sub>	665 nM	
MC-PEG <sub>48</sub>	776 nM	
MC-PEG <sub>4</sub> -(PEG <sub>8</sub> ) <sub>3</sub>	913 nM	
MC-PEG <sub>4</sub> -(PEG <sub>24</sub> ) <sub>3</sub>	> 1 mM	

Table 1. Impact of PEGylation on FcyRIIIa binding, assessed by biolayer interferometry

## Fc PEGylation is a general approach for modulating Fc-FcγR interactions

- Simple, conjugatable format impact on FcγRIIIa is generally applicable to any non-fucosylated antibody
- Effect of PEGylation was assessed using FcγRIIIa NFAT signaling reporter assays:




**Figure 1**. Impact of PEGylation on Fc<sub>y</sub>RIIIa binding for trastuzumab (top) and obinutuzumab (bottom) assessed using a Jurkat FcγRIIIa NFAT signaling assay.


Figure 4. Antitumor activity of CD40 antibodies and PEG conjugates in humanized CD40 mice with A20 tumors expressing human CD40. The conjugate bearing an unstable maleimide, SEA-CD40-MC-PEG12(8) had increased activity over a conjugate bearing a stable maleimide linkage, indicating that Fc impairment is reversible.(MP = maleimidopropyl)

## Fc binding and function can be restored upon maleimide deconjugation

### Evaluation of maleimide reversibility ex vivo and in vivo



**Figure 2.** The reversibility of maleimide linkage and antibody effector function was assessed by Jurkat FcyRIIIa NFAT reporter assay following incubation ex vivo in rat plasma at 37 °C



20000-10000

IL-1RA MCP-

**Figure 5.** Cytokine levels and total antibody concentration at 0.3 mg/kg dose of test article in cynomolgus macacques. SEA-CD40 (N=10), SGN-40 & SEA-CD40-MC-PEG<sub>12</sub>(8) (N=2 each).

# depletion

• Delayed but maximal effect is consistent with reversible attenuation of Fc function **Total B Cells** 


Figure 6. ADCC-mediated B cell depletion in non-human primates after administration of 0.3 mg/kg of test article in cynomolgus macacques. SEA-CD40 (N=10), SGN-40 and SEA-CD40-MC-PEG<sub>12</sub>(8) (N=2 each).

# Conclusions


- A simple and tunable conjugation-based method to reversibly modulate Fc-Fc $\gamma$ R interactions was developed.
- Technology is modular and widely applicable to other effectorfunction enhanced antibodies.
- Application to a CD40 agonist mitigates systemic cytokines while increasing exposure and maintaining efficacy.
- preferred for certain antibodies/targets.
- Fully reversible methodology has also been developed and may be

### Fc PEGylation dramatically reduces peripheral cytokines despite increased exposure and similar PD effects

### Fc PEGylation results in dramatic reductions in peripheral cytokine production with SEA-CD40 with increased exposure



# PEGylated conjugate drives delayed, but maximal B cell



DISCLOSURES: All authors are employees of and/or hold stock in Seagen Inc.



<sup>1.</sup> Advani, R., et al. Phase I study of the humanized anti-CD40 monoclonal antibody Dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Clin. Onc. 2009, 27, 4371. DOI: 10.1200/JCO.2008.21.3017 2. Bajor, D.L., et al. Preliminary results of a Phase 1 study of SEA-CD40, gemcitabine, Nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). J. Clin. Onc. 2022, 40, no. 4\_suppl. DOI: 10.1200/JCO.2022.40.4\_suppl.559